CPMD · Cannapharmarx, Inc.
$0.00
At close · Oct 20
View the 10-K filed Mar 31, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Customer concentration
— top customer 63% of revenue
One customer — 63% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company also recognized revenue of $861,476 (2024 - $nil) from the sale of cannabis products to a pharmaceutical company based in Germany. This comprised 63% of the revenues generated during the year ended December 31, 2025.”
One customer — 29% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company recognized revenue of $394,633 (2024 - $770,265) from Cantek (Note 12), which was 29% of the total revenue (2024 - 94%).”
Market Cap
$1.42M
Shares
708.69M
Volume · Oct 20
5900
Avg daily vol (3M)
67.59K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.01
Avg vol 30d56K
Short int6K · 0.0% float · 1.0d
Short vol15%
DataJan 2020–Oct 2026
Filing10-Q · Aug 18
Up next
filed Aug 18, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.70M
Trailing 12 months
Net income (TTM)
−$11.32M
Trailing 12 months
Revenue growth YoY
+19.3%
Year over year
Operating margin
-170.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
-58.3%
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
0%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
16%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−58%
trailing
YTD return
−62%
this year
Relative strength
−66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+66%
Y/Y
Gross margin
-153%
expanding
EPS growth
0%
Y/Y
Free cash flow
$-794.6K
Balance sheet
$6.2M
net debt
Quant / Vol
risk profile
Volatility
372%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
20.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
16%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 16%
Range high $0
vs 200-day avg -44%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CPMD
this stock
Cannapharmarx, Inc.
|
$1.42M | -61.5% | +66.1% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CPMD | +0.0% | -16.7% | -58.3% | +0.0% | -61.5% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +1.2% | -16.1% | -66.4% | -0.8% | -74.3% |